imaxitinib

Developed for: head and neck squamous cell carcinoma
Investigated by: Second Affiliated Hospital, School of Medicine, Zhejiang University

today NCT07457346 · Ph 2

202620272028

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 2	NCT07457346	Jan 2026 → Aug 2028 expected	head and neck squamous cell carcinoma	Second Affiliated Hospital, School of Medicine, Zhejiang University	Recruiting	No outcome recorded

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	imaxitinib	ClinicalTrials.gov intervention name — accepted as the source's own label NCT07457346 ↗
Route	Oral	“patients orally take 4mg of imaxitinib daily” NCT07457346 ↗